[1] Gupta AK, Chwetzoff E, Del Rosso J, et al.Hepatic safety of itraconazole. J Cutan Med Surg, 2002, 6:210-213. [2] Gupta AK, Shear NH. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol, 1999, 38Suppl 2:40-52. [3] Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine:results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol, 1997, 133:1213-1219. [4] Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol, 2000, 41:42-45. [5] Callen JP, Hughes AP, Kulp-Shorten C. et al. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine:a report of 5 cases. Arch Dermatol, 2001, 137:1196-1198. [6] Stricker BH, Van Riemsdijk MM, Sturkenboom MC, et al. Taste loss to terbinafine:a case-control study of potential risk factors.Br J Clin Pharmacol, 1996, 42:313-318. [7] Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. Br J Dermatol, 1999,140:1196-1997. [8] Tsai HH, Lee WR, Hu CH. Isolated thrombocytopenia associated with oral terbinafine.Br J Dennatol, 2002, 147:627-628. [9] Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf,2000, 22:33-52. [10] Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician, 2001, 63:663-672, 677-678. [11] Ajit C, Suvannasankha A, Zaefi N, et al.Terbinafine-associated hepatotoxicity. Am J Med Sci, 2003, 325:292-295. [12] Agarwal K, Manas DM, Hudson M.Terbinafine and fulminant hepatic failure.N Engl J Med, 1999, 340:1292-1293. [13] Gupta AK, del Rosso JQ, Lynde CW, et al.Hepatitis associated with terbinafine therapy:three case reports and a review of the literature. Clin Exp Dermatol, 1998, 23:64-67. [14] Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine:insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol, 2001, 14:175-181. [15] Madani S, Barilla D, Cramer J, et al. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol, 2002, 42:1211-1218. [16] Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation, 2002, 74:688-695. [17] Adriaenssens B, Roskams T, Steger P, et al.Hepatotoxicity related to itraconazole:report of three cases. Acta Clin Belg, 2001, 56:364-369. [18] Lavrijsen APM(杨晋芳摘).与伊曲康唑有关的肝损伤.国外医学皮肤性病学分册,1993.19:244-245. [19] Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol, 1999, 41:237-249. [20] 虞瑞尧.氟康唑的药理及其临床应用.新药与临床,1992,11:245-248. [21] Guillaume MP, De Prez C, Cogan E. Subacute mitochondrial liver disease in a patient with AIDS:possible relationship to prolonged fluconazole administration. Am J Gastreenterol, 1996, 91:165-168. [22] Scher RK, Breneman D, Rich P, et al. Onceweekly fluconazole (150, 300, or 450mg)in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol, 1998, 38:S77-86. [23] Wolf R, Wolf D, Kuperman S. Focal nodular hyperplasia of the liver after intraconazole treatment. J Clin Gastroenterol, 2001,33:418-420. |